You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How do you treat a Zepbound® (tirzepatide) overdose?
In the event of an overdosage, contact Poison Help Line or a medical toxicologist for overdosage management recommendations.
See important safety information, including boxed warning, in the attached prescribing information.
Approved Dosages
The recommended starting dose of tirzepatide for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks. The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.1
After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose.1
Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage.1
The recommended maintenance dosage is 5, 10, or 15 mg injected subcutaneously once weekly for weight reduction and long-term weight maintenance, and 10 mg or 15 mg injected subcutaneously once weekly for obstructive sleep apnea.1
Overdose
In the event of an overdosage, contact the Poison Help Line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.1
Appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.1
A period of observation and treatment for these symptoms may be necessary, considering the half-life of tirzepatide is approximately 5 days.1
Enclosed Prescribing Information
ZEPBOUND® (tirzepatide) injection, for subcutaneous use, Lilly
Reference
- Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
Date of Last Review: August 18, 2026